Tracking molecules made by the human microbiome | LabRulez LCMS

Tracking molecules made by the human microbiome

RECORD | Already taken place Tu, 9.8.2022
Both targeted and untargeted mass spectrometry approaches have been applied to identify the metabolites produced by intestinal bacteria that reach physiologically relevant levels in the systemic circulation.
Select Science: Tracking molecules made by the human microbiome

Select Science: Tracking molecules made by the human microbiome

In the words of Albert Einstein, "We cannot solve our problems with the same thinking we used when we created them." It takes outside the box thinking to continue to innovate and push the limits of what is possible. Each day you are your team work tirelessly to push those boundaries and create a better world, and Agilent is here to help you every step of the way. Instrument intelligence and innovation is of utmost importance, and together we can discover endless possibilities.

An enduring theme in human microbiome research has been understanding how trillions of bacteria in the human intestinal tract impact our physiology and immune function – likely through the metabolites they produce.

The Memorial Sloan Kettering Cancer Center, has focused on research of subjects undergoing allogeneic hematopoietic cell transplant (allo-HCT), a curative treatment for hematopoietic malignancies. Previous research work from our Center has demonstrated the intestinal microbiome is the primary reservoir for pathogenic bacterial species and can translocate into the systemic circulation. Beyond infection risk, recent research evidence also implicates intestinal microbiota diversity (and the metabolites produced) in shaping the emerging immune system following allo-HCT.

Both targeted and untargeted mass spectrometry approaches have been applied to identify the metabolites produced by intestinal bacteria that reach physiologically relevant levels in the systemic circulation. Applying a combination of analytical and data analysis strategies allows correlation of intestinal microbiome diversity with the circulating levels of many bioactive metabolites and investigate their impact on immune cell function.

For Research Use Only. Not for use in diagnostic procedures.

Key learning objectives
  • How mass spec can be applied to metabolomics research
  • Biomarker discovery in microbiome research
Who should attend?
  • Researchers interested in metabolomics and biomarker discovery

Presenter: Justin R. Cross, Ph.D. (Director, Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center)

SelectScience
 

Related content

Simultaneous analysis of drug substances according to USP assay and impurity methods

Applications
| 2022 | Thermo Fischer Scientific
Instrumentation
HPLC
Manufacturer
Thermo Fischer Scientific
Industries
Pharma & Biopharma

Matrix Matching or Isotope Dilution? A Comparison of Two Quantitation Approaches to Determine PFAS in Dairy Milk

Applications
| 2022 | Waters
Instrumentation
LC/MS, LC/MS/MS, LC/QQQ
Manufacturer
Waters
Industries
Food & Agriculture

Food Metabolomics of Alcoholic Beverage Using Single-Quadrupole Mass Spectrometer — Oligosaccharide and Polysaccharide Profiling —

Applications
| 2022 | Shimadzu
Instrumentation
LC/MS, LC/SQ
Manufacturer
Shimadzu
Industries
Food & Agriculture

Demonstrating the Applicability of the ACQUITY™ Premier Binary System for Long Shallow Gradient Peptide Mapping Analysis

Applications
| 2022 | Waters
Instrumentation
HPLC
Manufacturer
Waters
Industries
Proteomics

Qualitative Analysis of the Components in Foods Using DART and the Quadrupole Time- of-flight Mass Spectrometer

Applications
| 2022 | Shimadzu
Instrumentation
LC/TOF, LC/HRMS, LC/MS, LC/MS/MS, DART
Manufacturer
Shimadzu
Industries
Food & Agriculture
Other projects
Follow us
More information
WebinarsAbout usContact usTerms of use

LabRulez s.r.o., all rights reserved.